Menu Search
Equities

GlaxoSmithKline Pharmaceuticals Ltd

GLAXO:NSI

GlaxoSmithKline Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,411.80
  • Today's Change46.80 / 1.98%
  • Shares traded288.89k
  • 1 Year change+41.87%
  • Beta0.4620
Data delayed at least 15 minutes, as of Nov 22 2024 10:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy1
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in INR

The 4 analysts offering 12 month price targets for GlaxoSmithKline Pharmaceuticals Limited have a median target of 2,929.00, with a high estimate of 3,250.00 and a low estimate of 2,550.00. The median estimate represents a 20.44% increase from the last price of 2,431.90.
High33.6%3,250.00
Med20.4%2,929.00
Low4.9%2,550.00

Dividends

In 2024, GlaxoSmithKline Pharmaceuticals Ltd reported a dividend of 32.00 INR, equaling last years dividend. The 3 analysts covering the company expect dividends of 30.33 INR for the upcoming fiscal year, a decrease of 5.21%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On Feb 12, 2024, earnings of 9.89 per share.
The next earnings announcement is expected on May 15, 2025.
Average growth rate+5.42%
GlaxoSmithKline Pharmaceuticals Limited reported annual 2024 earnings of 26.35 per share on May 17, 2024.
Average growth rate+36.41%
More ▼

Revenue history & estimates in INR

GlaxoSmithKline Pharmaceuticals Limited had 2nd quarter 2025 revenues of 10.11bn. This missed the 10.33bn consensus estimate of the 4 analysts following the company. This was 32.71% above the prior year's 2nd quarter results.
Average growth rate+2.83%
GlaxoSmithKline Pharmaceuticals Limited had revenues for the full year 2024 of 34.54bn. This was 6.21% above the prior year's results.
Average growth rate+2.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.